Bristol-Myers Squibb Co vs Open Text Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while Open Text Corporation trades at $23.52 (market cap $5.80B). The key difference: Bristol-Myers Squibb Co is far larger — about 22.4× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.67%). Which is the better fit depends on your goals.
| BMY | OTEX | |
|---|---|---|
Market Cap | $129.94B | $5.80B |
Sector | Health | Technology |
52-Week High | $65.89 | $39.69 |
52-Week Low | $42.60 | $20.01 |
Enterprise Value | $163.92B | $10.81B |
Dividend Yield | 3.96% | 4.67% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Open Text Corporation (OTEX) trades at $23.27, down 5.87% over the past day, with a bullish technical signal despite recent weakness. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.23 versus $1.02 expected, and maintains solid fundamentals including a 73.74% gross margin and 12.26% net income margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe.
Outlook remains positive with a consensus price target of $29.33 implying 26% upside, supported by earnings beats and strategic AI investments. Risks include high debt levels and competitive pressures in the software sector. The stock offers value with a P/E of 9.29 and a 4.7% dividend yield.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →